Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Factors for Second-line Treatment of Advanced Non-small-cell Lung Cancer: Retrospective Analysis at a Single Institution

  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Platinum-hased chemotherapy for advanced non-small cell lung cancer (NSCLC) is still considered the first choice, presenting a modest survival advantage. However, the patients eventually experience disease progression and require second-line therapy. While there are reliable predictors to identify patients receiving first-line chemotherapy, very little knowledge is available about the prognostic factors in patients who receive second-line treatments. The present study was therefore performed. Methods: We retrospectively reviewed 107 patients receiving second-line treatments from August 2002 to March 2012 in the Dicle University, School of Medicine, Department of Medical Oncology. Fourteen potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Result: The results of univariate analysis for overall survival (OS) were identified to have prognostic significance: performance status (PS), stage, response to first-line chemotherapy response to second-line chemotherapy and number of metastasis. PS, diabetes mellitus (DM), response to first-line chemotherapy and response to second-line chemotherapy were identified to have prognostic significance for progression-free survival (PFS). Multivariate analysis showed that PS, response to first-line chemotherapy and response to second-line chemotherapy were considered independent prognostic factors for OS. Furthermore, PS and response to second-line chemotherapy were considered independent prognostic factors for PFS. Conclusion: In conclusion, PS, response to first and second-line chemotherapy were identified as important prognostic factors for OS in advanced NSCLC patients who were undergoing second-line palliative treatment. Furthermore, PS and response to second-line chemotherapy were considered independent prognostic factors for PFS. It may be concluded that these findings may facilitate pretreatment prediction of survival and can be used for selecting patients for the correct choice of treatment.

Keywords

References

  1. Azzoli CG, Baker Jr S, Temin S, et al (2009). American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 27, 6251-66. https://doi.org/10.1200/JCO.2009.23.5622
  2. Boyle P, Ferlay J (2004). Cancer incidence and mortality in Europe. Ann Oncol, 16, 481-8.
  3. Ciuleanu T, Stelmakh L, Clicenas S, et al(2012). Efficacy and safety of erlotinib versus chemotherapy in secondline treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol, 13, 300-8. https://doi.org/10.1016/S1470-2045(11)70385-0
  4. Di Maio M, Lama N, Morabito A, et al (2010). Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer, 46, 735-43 https://doi.org/10.1016/j.ejca.2009.12.013
  5. Di Maio M, Krzakowski M, Fougeray R, Kowalski DM, Gridelli C (2012). Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: External validation in a phase III trial comparing vinflunine with docetaxel. Lung Cancer, Feb 21
  6. Hanna N, Shepherd FA, Fossella FV, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97. https://doi.org/10.1200/JCO.2004.08.163
  7. Hotta K, Fujiwara Y, Kiura K, et al (2007). Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thoracic Oncol, 2, 402-7. https://doi.org/10.1097/01.JTO.0000268673.95119.c7
  8. Kim JG, Ryoo BY, Park YH, et al (2008). Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol, 61, 301-7.
  9. Krishnan S, Rana V, Janjan NA, et al (2006). Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 107, 2589-96. https://doi.org/10.1002/cncr.22328
  10. Mitry E, Douillard JY, Van Cutsem E, et al (2004). Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial. Ann Oncol, 15, 1013-7. https://doi.org/10.1093/annonc/mdh267
  11. Scartozzi M, Mazzanti P, Giampieri R, et al (2010). Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: selecting the unselectable? Lung Cancer, 68, 433-7. https://doi.org/10.1016/j.lungcan.2009.07.008
  12. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  13. Shepherd FA (1993). Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol, 5, 310-22. https://doi.org/10.1097/00001622-199303000-00010
  14. Wataya H, Okamoto T, Maruyama R, et al (2009). Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. Lung Cancer, 64, 341-5. https://doi.org/10.1016/j.lungcan.2008.09.005
  15. Weiss GJ, Rosell R, Fossella F, et al (2007). The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol, 18, 453-60.
  16. Zietemann V, Duell T (2011). Prevalence and effectiveness of first-, second-, and third-line systemic therpy in a cohort of unselected patients with advanced non-small cell lung cancer. Lung Cancer, 73, 70-7. https://doi.org/10.1016/j.lungcan.2010.10.017

Cited by

  1. Analysis of prognostic factors for overall survival in patients with advanced non-small cell lung cancer treated with second line chemotherapy vol.02, pp.03, 2013, https://doi.org/10.4236/alc.2013.23007
  2. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2413
  3. Differences in Epidermal Growth Factor Receptor Gene Mutations and Relationship with Clinicopathological Features in NSCLC Between Uygur and Han Ethnic Groups vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2879
  4. Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6799
  5. Edition Staging System vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2465
  6. Outcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution vol.77, pp.1, 2014, https://doi.org/10.4046/trd.2014.77.1.13